The 2016 Biotechnology Awards showcase the very best talent, dedication and discoveries from firms working in the field of healthcare.
Alacris’ revolutionary systems medicine modelling approach (ModCell™), to better match patients to therapies (‘virtual patients’) and therapies to patients (‘virtual clinical trials’) and Alacris’ unique oncogenomic pipeline was selected by the jury for “Best for Cancer Patient Custom Therapy Identification”..
Our revolutionary systems medicine modelling approach (ModCell™), to better match patients to therapies (‘virtual patients’) and therapies to patients (‘virtual clinical trials’) convinced the jury. Rather than testing novel therapeutic strategies on actual patients, with the associated risks to their health and wellbeing, at Alacris computer models are deployed, based on millions of data points to carry out virtual patient modelling.
Nathan Angell, Awards Co-ordinator, commented: “With these awards, we recognise professionals whose hard work and dedication has changed the shape of the healthcare industry, as well as contributing to the saving of many lives. I am proud and honoured to be able to congratulate and reward all of our deserving winners, and I wish them continued success in the years to come.”
Read the ghp winner’s supplement here.
